Welcome to our dedicated page for Precision Optics news (Ticker: POCI), a resource for investors and traders seeking the latest updates and insights on Precision Optics stock.
Precision Optics Corporation, Inc. reports recurring business developments in advanced optical instruments for the medical and defense/aerospace industries. The company designs, develops and manufactures custom optical medical devices, endoscopes, endocouplers and related optical assemblies, with news frequently covering single-use endoscopy programs and customer production orders.
Updates for POCI also include product-development work for aerospace and defense applications, including small-diameter borescope systems used in jet-engine inspection. Company announcements commonly address fiscal-period operating results, conference calls, customer program activity, backlog and pipeline commentary, and capital-structure actions involving its Nasdaq-listed common stock.
Precision Optics (POCI) received approximately $1.3 million in follow-on production orders from a large U.S. defense contractor for complex optical assemblies first manufactured in 2018.
The company believes the underlying defense program could remain in production for at least the next ten years. Precision Optics and its customer expect to negotiate a long-term manufacturing agreement in the coming months, with a structured order framework aimed at reducing order gaps and supporting more continuous manufacturing. The company said this structure is expected to preserve manufacturing continuity and knowledge, improve planning and throughput, and generate cost efficiencies while providing a strong base of recurring business for its micro-optics group.
Precision Optics (Nasdaq: POCI) announced the appointment of Peter Thier as Senior Vice President of Sales and Marketing, effective August 18, 2026. According to Precision Optics, Thier will lead the company’s sales and marketing strategy across its medical, defense and aerospace markets.
Thier brings more than 30 years of experience in sales, business development, strategy and commercial leadership in medical technology, life sciences and advanced product development. In connection with his hiring, the board approved an inducement stock option for 50,000 shares of common stock, granted under Nasdaq Rule 5635(c)(4). The option has a 10‑year term, an exercise price equal to the Nasdaq closing price on August 18, 2026, and vests in three equal annual installments over three years, subject to continued service.
Precision Optics (Nasdaq: POCI) will participate in a webcast presentation at the Lytham Partners 2026 Consumer & Technology Investor Summit, held virtually on Tuesday, August 18, 2026. The company’s presentation is scheduled for 2:30 p.m. ET that day.
The webcast can be accessed via the summit home page at https://lythampartners.com/cts2026/ or directly at https://lythampartners.com/cts2026/poci, with a replay available through the same links. Founded in 1982, Precision Optics designs and manufactures advanced micro-optics, 3D imaging and digital imaging products for healthcare and defense/aerospace markets.
Precision Optics (Nasdaq:POCI) will present at the Planet MicroCap Las Vegas 2026 Investor Conference on Wednesday, June 17, 2026, at 11:00 a.m. Pacific time at the Bellagio Resort & Hotel in Las Vegas.
The presentation will be available via live webcast, and management will also hold in-person 1x1 investor meetings on June 17-18 for registered conference attendees.
Precision Optics (Nasdaq: POCI) will participate in the virtual Lytham Partners Spring 2026 Investor Conference on May 28, 2026. The Company will host a webcast presentation and conduct one-on-one investor meetings.
The webcast is scheduled for 1:00 p.m. ET and will be available for replay after the event.
Precision Optics (NASDAQ:POCI) reported record Q3 FY2026 revenue of $8.7 million, up about 108% year-over-year, with production revenue at $7.6 million and engineering revenue at $1.1 million. Gross margin rose to 23.6%, net loss narrowed to $0.1 million, and adjusted EBITDA was $0.3 million.
The company raised FY2026 revenue guidance to $29–$31 million and tightened adjusted EBITDA guidance to a loss of $2.5–$2.7 million. It completed an oversubscribed $10 million public offering and received a $3.5 million follow-on ophthalmic order.
Precision Optics (Nasdaq: POCI) scheduled its Q3 fiscal 2026 earnings conference call for Wednesday, May 13, 2026 at 5:00 p.m. ET. The company will release financial results and file its 10-Q after market close on May 13, 2026, followed by the call.
Call access includes dial-in numbers, a live webcast, and seven-day teleconference and webcast replays.
Precision Optics (NASDAQ: POCI) received a follow-on production order of approximately $3.5 million for a single-use ophthalmic endoscope. Shipments are expected to commence shortly and be fulfilled over 12–15 months, supporting the customer’s transition from limited launch to full launch.
The program is Precision Optics’ second single-use design to enter production and follows an initial production order announced in November 2024. Management cites multi-year development and IP investments as enabling the shift to single-use endoscopy.
Precision Optics (NASDAQ: POCI) priced an upsized underwritten public offering of 2,777,777 shares at $3.60 per share, generating roughly $10.0 million of gross proceeds. The underwriter has a 45‑day option to buy up to 416,667 additional shares. The offering is expected to close on or about March 30, 2026, and net proceeds will be used for working capital and general corporate purposes. Insiders including the CEO, CFO and COO participated at the public price. Lucid Capital Markets is sole book‑running manager.
Precision Optics (NASDAQ: POCI) announced on March 26, 2026 that it is commencing an underwritten public offering of common stock (or common stock equivalents), subject to market conditions and with no assurance as to timing, size, or terms.
Lucid Capital Markets is the sole book-running manager, and the offering is being made under a shelf registration on Form S-3 declared effective June 14, 2024; a preliminary prospectus supplement will be filed with the SEC.